EMEA-001970-PIP02-17
Key facts
| Active substance |
SER-109 (Eubacterial Spores, Purified Suspension, Encapsulated)
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0390/2018
|
| PIP number |
EMEA-001970-PIP02-17
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of Clostridium difficile infection
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Seres Therapeutics Netherlands B.V.
E-mail: akurowski@serestherapeutics.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|